TERBUTALINE SULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Terbutaline Sulfate patents expire, and when can generic versions of Terbutaline Sulfate launch?
Terbutaline Sulfate is a drug marketed by Areva Pharms, Chartwell Injectable, Dr Reddys, Epic Pharma Llc, Fresenius Kabi Usa, Hikma Farmaceutica, Impax Labs, Lannett Co Inc, and Twi Pharms. and is included in nine NDAs.
The generic ingredient in TERBUTALINE SULFATE is terbutaline sulfate. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Terbutaline Sulfate
A generic version of TERBUTALINE SULFATE was approved as terbutaline sulfate by IMPAX LABS on June 26th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TERBUTALINE SULFATE?
- What are the global sales for TERBUTALINE SULFATE?
- What is Average Wholesale Price for TERBUTALINE SULFATE?
Summary for TERBUTALINE SULFATE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 11 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,397 |
| Drug Prices: | Drug price information for TERBUTALINE SULFATE |
| What excipients (inactive ingredients) are in TERBUTALINE SULFATE? | TERBUTALINE SULFATE excipients list |
| DailyMed Link: | TERBUTALINE SULFATE at DailyMed |
Recent Clinical Trials for TERBUTALINE SULFATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke Health | Phase 2/Phase 3 |
| Kanecia Zimmerman, MD MPH | Phase 2/Phase 3 |
| The Emmes Company, LLC | Phase 2/Phase 3 |
Medical Subject Heading (MeSH) Categories for TERBUTALINE SULFATE
Anatomical Therapeutic Chemical (ATC) Classes for TERBUTALINE SULFATE
US Patents and Regulatory Information for TERBUTALINE SULFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Areva Pharms | TERBUTALINE SULFATE | terbutaline sulfate | INJECTABLE;INJECTION | 200122-001 | Nov 8, 2013 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Impax Labs | TERBUTALINE SULFATE | terbutaline sulfate | TABLET;ORAL | 075877-001 | Jun 26, 2001 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Epic Pharma Llc | TERBUTALINE SULFATE | terbutaline sulfate | INJECTABLE;INJECTION | 078151-001 | Jan 7, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Twi Pharms | TERBUTALINE SULFATE | terbutaline sulfate | TABLET;ORAL | 211832-002 | Jun 19, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Impax Labs | TERBUTALINE SULFATE | terbutaline sulfate | TABLET;ORAL | 075877-002 | Jun 26, 2001 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Injectable | TERBUTALINE SULFATE | terbutaline sulfate | INJECTABLE;INJECTION | 076770-001 | Apr 23, 2004 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
